Search Browse Earnings

Autolus Therapeutics plc

Nasdaq:AUTL

Biological Products, (No Diagnostic Substances)·LONDON, X0

Overview All Filings Sum Fin Credit Insiders Governance

Overview All Filings Sum Fin Credit Insiders Governance

Summary Financials

Autolus Therapeutics plc — SlamSEC

Revenue

$1.7M

+0.3% YoY

FY 2024

Adj. EBITDA

-$173.1M

-10196.5% margin

FY 2024

Net Income

-$208.4M

-12272.3% margin

FY 2024

EPS (Diluted)

-$1.20

FY 2024

Stock Price

$1.44

-1.4%

2026-03-13

52W Range

$1.10 – $2.70

P/E Ratio

-1.2x

Market Cap

$383.2M

Cash

$239.6M

FY 2024

Total Debt

$285,000

FY 2019

Net Cash

$239.3M

FY 2019

Enterprise Value

$144.0M

Debt / EBITDA

1.4x

FY 2024

EV / EBITDA

-0.8x

Employees

—